UT Health San Antonio and UT Health Houston announced a landmark agreement Friday to grant exclusive global licenses for two biologic therapeutics to AlaMab Therapeutics Inc., a subsidiary of CSPC Pharmaceutical Group, in a deal that could be worth up to $114 million.
